BioNotebook: NPS gets orphan status in Europe, Neuralstem raises $20 million, Salix completes buyout of Santarus
This article was originally published in Scrip
NPS Pharmaceuticals gets an orphan drug designation for it hormone disorder treatment Natpara in the EU. Stem cell company Neuralstem raises almost $20 million in a stock sale, and Salix Pharmaceuticals said it wrapped up its deal for rival Santarus.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.